Results 111 to 120 of about 55,609,055 (315)

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Position Paper on Road Map for RNA Virus Research in India

Frontiers in Microbiology, 2018
The Indian subcontinent with its population density, climatic conditions, means of subsistence, socioeconomic factors as well as travel and tourism presents a fertile ground for thriving of RNA viruses. Despite being pathogens of huge significance, there
Guruprasad R. Medigeshi, Katja Fink, Nagendra R. Hegde   +2 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Study designs: Part 5 – interventional studies (II)

Perspectives in Clinical Research, 2019
In the fifth piece of this series on research study designs, we continue the discussion on interventional studies (clinical trials), in which the investigator decides whether or not a particular participant receives the exposure (or intervention).
Rakesh Aggarwal, Priya Ranganathan
doaj   +1 more source

Understanding implementability in clinical trials: a pragmatic review and concept map.

BackgroundThe translation of evidence from clinical trials into practice is complex. One approach to facilitating this translation is to consider the 'implementability' of trials as they are designed and conducted.
Australian Clinical Trials Alliance Reference Group on Impact and Implementation of CTN Trials, Sharplin, Greg, Webb, Steven A, Green, Sally, Middleton, Philippa, Cumpston, Miranda S   +5 more
core   +1 more source

Clinical trials profile: Professionals and sites

, 2010
Clinical trial is considered a breakthrough method in medicine and essential to the development of new drugs. Clinical trials that comply with international and national regulations require an appropriate infrastructure and team qualification.
Marcelo E. Nita, Flair J. Carrilho, ONO-NITA, Suzane Kioko, BARBOSA, Fernanda R., Helena S. Paschoale, NITA, Marcelo E., Fernanda R. Barbosa, CARRILHO, Flair J., Suzane Kioko Ono-Nita, PASCHOALE, Helena S.   +9 more
core   +1 more source

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination : a phase 3 randomized, controlled trial in children and young infants at 11 African sites [PDF]

, 2014
A malaria vaccine could be an important addition to current control strategies. We report the safety and vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria transmission.; 6,537 ...
RTS, S. Clinical Trials Partnership, RTS,S Clinical Trials Partnership, The RTS,S Clinical Trials Partnership (2014) (614272)   +2 more
core   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials

Frontiers in Psychology, 2015
The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome(DS) has boosted a number of clinical trials in this population.
Susana ede Sola, Susana ede Sola, Rafael ede la Torre, Rafael ede la Torre, Rafael ede la Torre, Gonzalo eSanchez-Benavides, Gonzalo eSanchez-Benavides, Bessy eBenejam, Aida eCuenca-Royo, Aida eCuenca-Royo, Laura edel Hoyo, Joan eRodriguez, Silvina eCatuara-Solarz, Judit eSanchez-Gutiérrez, Ivan eDueñas-Espin, Ivan eDueñas-Espin, Gimena eHernandez, Gimena eHernandez, Jordi ePeña-Casanova, Jordi ePeña-Casanova, Klaus eLangohr, Klaus eLangohr, Sebastià eVidela, Henri eBléhaut, Magi eFarré, Magi eFarré, Mara eDierssen, Mara eDierssen, the eTESDAD Study Group   +28 more
doaj   +1 more source

Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression [PDF]

, 2012
Background: Randomized, double-blind, placebo-controlled trials constitute the gold standard in clinical research when testing the efficacy of new psychopharmacological interventions in the treatment of major depression.
Berger Michael, Dittmann, Sandra, Riedel Michael, Sophia, Frangou, Emanuel Severus, Bauer Michael, Severus, Emanuel, Pfennig Andrea, Florian Seemüller, Sophia Frangou, Michael, Bauer, Michael Bauer, Michael Riedel, Berger, Michael, Michael, Obermeier, Andrea, Pfennig, Michael Obermeier, Obermeier Michael, Seemüller Florian, Andrea Pfennig, Michael Berger, Hans-Jürgen, Möller, Dittmann Sandra, Michael, Riedel, Severus Emanuel, Frangou Sophia, Seemüller, Florian, Möller Hans-Jürgen, Sandra Dittmann, Hans-Jürgen Möller   +29 more
core   +2 more sources